Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.72 |
| ▸ | TDP2 | O95551 | 8/20 | 0.71 |
| ▸ | FABP7 | O15540 | 2/20 | 0.55 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.55 |
| ▸ | FABP3 | P05413 | 1/20 | 0.55 |
| ▸ | KMO | O15229 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6215760 | 0.89 | TDP2 (0.71) | CRBNTDP2KMOPGR | |
| SCHEMBL30731586 | 0.88 | CRBN (0.69) | CRBNTDP2FABP7FABP5FABP3 | |
| SCHEMBL29899565 | 0.87 | TDP2 (0.72) | CRBNTDP2FABP7FABP5FABP3 | |
| SCHEMBL4408889 | 0.85 | TDP2 (0.65) | CRBNTDP2FABP7FABP5FABP3 | |
| SCHEMBL23175435 | 0.84 | CRBN (1.00) | CRBNTDP2FABP7FABP5FABP3 | |
| SCHEMBL29899574 | 0.84 | CRBN (1.00) | CRBNTDP2FABP7FABP5FABP3 | |
| SCHEMBL4416949 | 0.84 | CRBN (0.66) | CRBNTDP2FABP7FABP5FABP3 | |
| SCHEMBL18010835 | 0.83 | TDP2 (1.00) | TDP2 | |
| SCHEMBL398818 | 0.83 | TDP2 (0.66) | CRBNTDP2GAACMA1AHR | |
| SCHEMBL29713338 | 0.83 | TDP2 (0.66) | CRBNTDP2GAACMA1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1259514-B9 | 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN INC (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1259514-B1 | 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN INC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1259514-A2 | 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6465507-B2 | ANTITUMOR AGENTS | SUGEN, INC. | 2002-10-15 | — | — | US | disclosed |
| US-20020042427-A1 | 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors | SUGEN, INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2001064681-A2 | 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042427-A1 | 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors | MAP3K20, MAP3K6, MAP3K3 | CRBN 1717/4885TDP2 1306/4885FABP7 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.